Ropivacaine

As a representative variety of long-acting amide local anesthetics, ropivacaine blocks the inflow of sodium ions into the cell membrane of nerve fibers to reversibly inhibit the conduction of nerve impulses. Its core advantage over traditional local anesthetics lies in the characteristic of separation of sensory and motor block: at low concentrations, it almost only blocks sensory nerves without affecting motor function. It is widely used in clinical scenarios such as surgical anesthesia, postoperative acute pain control, and labor analgesia, covering multiple departments including surgery, obstetrics and gynecology, and pain management, and meets the analgesic needs of both adult and pediatric patients. It is one of the basic drugs for current perioperative pain management.

At present, the global market size of ropivacaine is stably above 1.2 billion US dollars, and the annual growth rate of the Chinese market maintains at 6%~8%. In 2023, the domestic terminal sales exceeded 3 billion yuan. From the perspective of competitive landscape, the original research product accounts for about 35% of the market share, and domestic generic drugs are continuously replacing it with cost advantages. At present, the generic preparations of nearly 20 enterprises have passed the consistency evaluation. After the implementation of volume-based procurement, the overall price has dropped by more than 70%, which further promotes the increase of clinical penetration rate, and the expansion space of the primary market is significant.

The original research enterprise of ropivacaine is AstraZeneca, with the original trade name Naropin. The core compound patent expired globally in 2011. The main dosage forms approved for the original product include ropivacaine hydrochloride injection, with conventional specifications such as 10ml:75mg, 10ml:100mg, 20ml:150mg, etc. It has been included in the *Catalogue of Reference Preparations for Chemical Drugs* of China, and is also a reference preparation included by the FDA. Up to now, there are more than 30 valid registration numbers of ropivacaine API on the API registration platform of China CDE, among which nearly 20 are in A status, and more than 15 domestic enterprises have obtained marketing approval for ropivacaine preparations. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for ropivacaine API, covering all categories of process impurities and degradation impurities. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All reference standards meet the requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can meet the full-process R&D needs such as impurity research, quality standard establishment, and consistency evaluation.